eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
1/2019
vol. 5
 
Share:
Share:
more
 
 
abstract:
Review paper

Expert group consensus regarding the place of ivabradine in therapy optimisation in patients with chronic heart failure

Marcin Barylski
,
Małgorzata Lelonek
,
Artur Mamcarz
,
Agnieszka Mastalerz-Migas

Online publish date: 2019/03/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Accelerated heart rate is a risk factor of general and cardiovascular mortality in different populations. The classical treatment to achieve heart rate reduction by β-blockers and calcium channel antagonists from the group of non-dihydropyridines (verapamil and diltiazem) is often limited by contraindications or adverse reactions. Ivabradine is a unique, modern drug, the mechanism of action of which is blocking the If current in the sinoatrial node. This translates into a reduction in heart rate – a parameter associated with poor prognosis in patients with heart failure. The following document contains the opinion of an expert group summarising current knowledge on ivabradine and its use in the population of patients with heart failure.
keywords:

therapy optimisation, heart failure, ivabradine

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe